Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics granted inducement equity awards to new Chief Financial Officer Matthew Gall and another new employee effective May 1, 2026. Gall received non-qualified stock options for 240,000 shares and 40,000 restricted stock units, while the other new hire received 199,650 options and 33,250 RSUs.
Key figures
- Exercise price
- 20.98
- Cfo rsus granted
- 40000
- Cfo options granted
- 240000
- New hire rsus granted
- 33250
- New hire options granted
- 199650
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.